Leonardo B C Brasiliense1, Morgan A Stanley2, Sanjeet S Grewal2, Harry J Cloft3, Eric Sauvageau4, Giuseppe Lanzino5, David Miller3, David F Kallmes3, Ricardo Hanel1. 1. Stroke and Cerebrovascular Center, Baptist Medical Center Jacksonville, Jacksonville, Florida, USA. 2. Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, USA. 3. Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. 4. Department of Lyerly Neurosurgery, Baptist Health, Jacksonville, Florida, USA. 5. Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND: The development of ischemic events is relatively common after endovascular interventions, and flow diverters may pose a particular threat owing to their increased technical complexity and high metal content. OBJECTIVE: To investigate the incidence and potential risk factors for thromboembolic lesions after treatment with a Pipeline embolization device (PED). METHODS: This prospective study included a total of 59 patients electively treated with a PED over 12 months. Postprocedural diffusion-weighted imaging sequences of the brain were obtained 24 h after interventions to detect ischemic lesions. Demographic data, aneurysm characteristics, antiplatelet management, and perioperative data were correlated with the rate of ischemic events. RESULTS: The incidence of silent ischemic events after use of a PED was 62.7% (37 patients) and neurological symptoms occurred in 8.1% of affected patients. Development of ischemic events was significantly associated with older patients (≥60 years; p=0.038). Routine use of platelet function assays and newer P2Y12 receptor inhibitors (ticagrelor) were not associated with fewer thromboembolic events. CONCLUSIONS: Thromboembolic events are relatively common after treatment with a PED with an incidence comparable to stent-assisted and conventional coiling but the risk of neurological morbidity from ischemic burden is low. Older patients are at particularly increased risk of thromboembolic events. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
BACKGROUND: The development of ischemic events is relatively common after endovascular interventions, and flow diverters may pose a particular threat owing to their increased technical complexity and high metal content. OBJECTIVE: To investigate the incidence and potential risk factors for thromboembolic lesions after treatment with a Pipeline embolization device (PED). METHODS: This prospective study included a total of 59 patients electively treated with a PED over 12 months. Postprocedural diffusion-weighted imaging sequences of the brain were obtained 24 h after interventions to detect ischemic lesions. Demographic data, aneurysm characteristics, antiplatelet management, and perioperative data were correlated with the rate of ischemic events. RESULTS: The incidence of silent ischemic events after use of a PED was 62.7% (37 patients) and neurological symptoms occurred in 8.1% of affected patients. Development of ischemic events was significantly associated with older patients (≥60 years; p=0.038). Routine use of platelet function assays and newer P2Y12 receptor inhibitors (ticagrelor) were not associated with fewer thromboembolic events. CONCLUSIONS:Thromboembolic events are relatively common after treatment with a PED with an incidence comparable to stent-assisted and conventional coiling but the risk of neurological morbidity from ischemic burden is low. Older patients are at particularly increased risk of thromboembolic events. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Seyed Mohammad Seyedsaadat; Leonardo Rangel Castilla; Giuseppe Lanzino; Harry J Cloft; Daniel J Blezek; Amy Theiler; Ramanathan Kadirvel; Waleed Brinjikji; David F Kallmes Journal: Neuroradiol J Date: 2019-04-03
Authors: D Atasoy; N Kandasamy; J Hart; J Lynch; S-H Yang; D Walsh; C Tolias; T C Booth Journal: AJNR Am J Neuroradiol Date: 2019-11-14 Impact factor: 3.825
Authors: Miklos Marosfoi; Frederic Clarencon; Erin T Langan; Robert M King; Olivia W Brooks; Takamisu Tamura; John M Wainwright; Matthew J Gounis; Srinivasan Vedantham; Ajit S Puri Journal: J Neurointerv Surg Date: 2017-07-08 Impact factor: 5.836
Authors: V Hellstern; M Aguilar Pérez; E Henkes; E Donauer; C Wendl; H Bäzner; O Ganslandt; H Henkes Journal: Cardiovasc Intervent Radiol Date: 2022-05-13 Impact factor: 2.797
Authors: Fawaz Al-Mufti; Eric R Cohen; Krishna Amuluru; Vikas Patel; Mohammad El-Ghanem; Rolla Nuoman; Neil Majmundar; Neha S Dangayach; Philip M Meyers Journal: Interv Neurol Date: 2018-10-16